Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
This study has been completed.
First Received: September 7, 2005   Last Updated: January 28, 2008   History of Changes
Sponsors and Collaborators: NovaCardia
Merck
Information provided by: NovaCardia
ClinicalTrials.gov Identifier: NCT00159614
  Purpose

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.


Condition Intervention Phase
Heart Failure, Congestive
Renal Insufficiency
 Drug: KW-3902IV
 Phase II

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study
Official Title: Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
Drug Information available for: Furosemide 1,3-Dipropyl-8-(3-noradamantyl)xanthine
U.S. FDA Resources

Further study details as provided by NovaCardia:

Primary Outcome Measures:
  • Comparison of KW-3902IV alone or with loop diuretic on renal function.

Estimated Enrollment: 30
Study Start Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion Criteria:

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159614

Locations
United States, California
san diego, California, United States
United States, Maryland
baltimore, Maryland, United States
United States, Massachusetts
boston, Massachusetts, United States
ayer, Massachusetts, United States
United States, Michigan
kalamazoo, Michigan, United States
United States, Tennessee
tullahoma, Tennessee, United States
Sponsors and Collaborators
NovaCardia
Merck
  More Information

No publications provided by NovaCardia

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007 Oct;13(8):609-17.

Study ID Numbers: CKI-203
Study First Received: September 7, 2005
Last Updated: January 28, 2008
ClinicalTrials.gov Identifier: NCT00159614     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by NovaCardia:
renal insufficiency
diuretic
heart failure, congestive

Study placed in the following topic categories:
Heart Failure
Renal Insufficiency
Heart Diseases
Urologic Diseases
Diuretics
 Cardiovascular Agents
Kidney Diseases
Furosemide
1,3-dipropyl-8-(3-noradamantyl)xanthine

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Diuretics
Physiological Effects of Drugs
Cardiovascular Agents
Pharmacologic Actions
 Urologic Diseases
Natriuretic Agents
Therapeutic Uses
Cardiovascular Diseases
Kidney Diseases
1,3-dipropyl-8-(3-noradamantyl)xanthine

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services